Keywords: fda, pulls, ketek, aecb, abs, market, french
FDA pulls Ketek from AECB and ABS market
Article | 22 December 2006
French drug major Sanofi-Aventis says that a US Food and Drug Administration Joint Advisory Committee has recognized the positive benefit-risk ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
